NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease.

Trial Profile

NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jan 2016 Study design has been changed from double blind to open label, also randomization has been removed as reported by ClinicalTrials.gov.
    • 18 Jan 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Feb 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top